Dr. Clay Siegall is a scientist and co-founded Seattle Genetics in 1998. Since then he has dedicated his life to the pursuit of genetic research and finding cures for disease such as cancer. Dr. Siegall received a Ph.D. in Genetics from George Washington
University and a B.S. in Zoology from the University of Maryland. As a scientist Clay has built up his company on the integrity of scientific principles and is committed to solid research in the modern era. Moreover, in line with his love of scientific research, Seattle Genetics offers grants to fund cancer research through the program which is known as the Independent Medical Education and Charitable Grants. In addition to his work with Seattle Genetics, he was recently made a board member of Mirna Therapeutics Inc and is also a member of the board of directors for Ultragenyx a pharmaceutical company. Dr Siegall has a net worth estimated to be $9,559,397.
In a recent article for the Seattle business mag, Seattle Genetics CEO Dr Clay Siegall was interviewed. The focus of the article was to highlight the growth of this pharma giant and to highlight the exceptional work they are doing in the fight against illness. Furthermore, seattle genetics is focused on breaking into the bigger, international pharmaceutical market and they are so determined to cure diseases like Hodgkin’s Lymphoma that they sold international commercial right to Takeda Oncology in a bid to raise capital for research into Adcetris (the company’s flagship drug). Growth of the company has not subsided with sales increasing by 45% since 2014. The total sales for 2016 were about $418 million. The company is working on 11 other drugs as yet unnamed in the hopes of fighting other types of cancer, and despite the political and economic climate stability he and his company will never give up the fight against cancer.